Proteros fragments, founded last summer to differentiate itself from its parent company's protein-crystallography business, this week announced its first deal, an agreement with Axikin Pharmaceuticals to discover lead compounds for inflammatory diseases.

Under the terms of the agreement, Proteros fragments, based in Martinsried, Germany, will "provide multidisciplinary research teams with the aim of generating multiple advanced lead series inhibiting a novel proprietary target protein," the two firms said in a joint statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

Popular Mechanics reports that Caltech researchers have built a prototype nanobot using DNA.

The Sacramento Bee writes that direct-to-consumer genetic testing connected a woman to sperm donor-conceived half siblings.

In PLOS this week: gene expression catalog for sheep, viral diversity among respiratory samples from camels, and more.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.